With 0.67 million shares changed hands, the volume of the stock remained heavier than its average volume of 33100.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $26.735 whereas the lowest price it dropped to was $25.5. The 52-week range on XOMA shows that it touched its highest point at $35.00 and its lowest point at $19.27 during that stretch. It currently has a 1-year price target of $89.00. Beta for the stock currently stands at 0.90.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of XOMA was down-trending over the past week, with a drop of -2.16%, but this was down by -1.58% over a month. Three-month performance dropped to -6.81% while six-month performance fell -5.42%. The stock gained 35.19% in the past year, while it has gained 1.60% so far this year. A look at the trailing 12-month EPS for XOMA yields -3.48 with Next year EPS estimates of -0.55. For the next quarter, that number is -0.30. This implies an EPS growth rate of 72.03% for this year and 51.33% for next year.
Float and Shares Shorts:
At present, 11.76 million XOMA shares are outstanding with a float of 11.68 million shares on hand for trading. On 2024-12-31, short shares totaled 0.15 million, which was 128.0 higher than short shares on 1732838400. In addition to Mr. Owen P. Hughes Jr. as the firm’s CEO & Director, Mr. Thomas M. Burns serves as its Senior VP of Finance & CFO.
Institutional Ownership:
Through their ownership of 0.65443003 of XOMA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, XOMA reported revenue of $734000.0 and operating income of -$1640000.0. The EBITDA in the recently reported quarter was -$1534000.0 and diluted EPS was -$1.59.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for XOMA since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With XOMA analysts setting a high price target of 123.0 and a low target of 55.0, the average target price over the next 12 months is 89.0. Based on these targets, XOMA could surge 360.67% to reach the target high and rise by 105.99% to reach the target low. Reaching the average price target will result in a growth of 233.33% from current levels.
Analysts have provided yearly estimates in a range of -$1.11783 being high and -$1.12247 being low. For XOMA, this leads to a yearly average estimate of -$1.1201500000000002. Based on analyst estimates, the high estimate for the next quarter is -$0.29 and the low estimate is -$0.29. The average estimate for the next quarter is thus -$0.29.
